Title : Improving Outcomes in Cardiovascular Diseases: A Review on Vorapaxar.

Pub. Date : 2021 Mar 19

PMID : 33758122






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Another recently published VORA-PRATIC (Vorapaxar in Patients with Prior Myocardial Infarction Treated with prasugrel and ticagrelor) study showed that among post-MI patients treated with potent P2Y12 inhibitors (prasugrel or ticagrelor), vorapaxar reduced platelet-driven global thrombogenicity, an effect that persisted, albeit attenuated, in the absence of aspirin. Prasugrel Hydrochloride purinergic receptor P2Y12 Homo sapiens
2 Another recently published VORA-PRATIC (Vorapaxar in Patients with Prior Myocardial Infarction Treated with prasugrel and ticagrelor) study showed that among post-MI patients treated with potent P2Y12 inhibitors (prasugrel or ticagrelor), vorapaxar reduced platelet-driven global thrombogenicity, an effect that persisted, albeit attenuated, in the absence of aspirin. Prasugrel Hydrochloride purinergic receptor P2Y12 Homo sapiens